Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa.

Dakiw Piaceski, A; Larouche, D; Ghani, K; Bisson, F; Cortez Ghio, S; Larochelle, S; Moulin, V J; Caruso, M; Germain, L

Dakiw Piaceski, A; Larouche, D; Ghani, K; Bisson, F; Cortez Ghio, S; Larochelle, S; Moulin, V J; Caruso, M; Germain, L.

Affiliation

Caruso M; Cancer Research Centre, Université Laval, Quebec City, Quebec, G1R 3S3, Canada.Manuel.Caruso@ crchudequebec.ulaval.ca.

Eur Cell Mater ; 35: 73-86, 2018 02 14.

Article in En | MEDLINE | ID: mdl-29441510

Subject(s)

Epidermolysis Bullosa Dystrophica/therapy; Genetic Therapy; Tissue Engineering; Cell Differentiation; Cell Line; Cell Proliferation; Collagen Type VII/genetics; Collagen Type VII/metabolism; Colony-Forming Units Assay; Epidermolysis Bullosa Dystrophica/pathology; Fibroblasts/pathology; Green Fluorescent Proteins/metabolism; Humans; Keratin-19/metabolism; Keratinocytes/pathology; Retroviridae/metabolism; Skin, Artificial; Transduction, Genetic

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Therapy / Epidermolysis Bullosa Dystrophica / Tissue Engineering Limits: Humans Language: En Journal: Eur Cell Mater Year: 2018 Document type: Article Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google